

10/567057
10567037 - GAO: 1/614
IAP9 Rec'd PCT/PTO 01 FEB 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	[to be assigned]
--------------------	------------------

Filing Date

First Named Inventor	Gert Daube
----------------------	------------

Art Unit

Examiner Name

Attorney Docket Number	AH / Le A 36 807
------------------------	------------------

Sheet	1	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Savitha Rao/

Date Considered	
--------------------	--

07/06/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.R./

Receipt date: 02/01/2006

10/567057
 IAP9 Rec'd PGT/PTO 01 FEB 2006 614

PTO/SB/08B (07-05)
 Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	[to be assigned]	
				Filing Date		
				First Named Inventor	Gert Daube	
				Art Unit		
Examiner Name						
Attorney Docket Number	AH / Le A 36 807					
Sheet	2	of	2			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Bansal, M. B., et al., "Activity of Difloxacin (A-56619) and A-56620 against Clinical Anaerobic Bacteria In Vitro", Antimicrobial Agents and Chemotherapy, 31(4): 619-621 (April 1987)	
	R2	Coulet, M., et al., "Pharmacokinetics of ibafloxacin Following intravenous and oral administration to healthy Beagle dogs", J. Vet. Pharmacol. Therap. 25: 89-97 (2002)	
	R3	Da Silva, A. D., et al., "Biological Activity and synthetic Metodologies for the Preparation of Fluoroquinolones, A Class of Potent Antibacterial Agents", Current Medicinal Chemistry, 10(1): 21-39 (2003)	
	R4	Goldstein, E. J. C., et al., In Vitro Activities of a New Des-Fluoroquinolone, BMS 284756, and Seven Other Antimicrobial Agents Against 151 Isolates of Eikenella corrodens", Antimicrobial Agents and Chemotherapy, 46(4): 1141-1143 (April 2002)	
	R5	Granneman, G. R., et al., "Difloxacin Metabolism and Pharmacokinetics in Humans after Single Oral Doses", Antimicrobial Agents and Chemotherapy, 30(5): 689-693 (November 1986)	
	R6	Hecht, D. W., et al., "Activities of Garenoxacin (BMS-284756) and Other Agents Against Anaerobic Clinical Isolates", Antimicrobial Agents and Chemotherapy, 47(3): 910-916 (March 2003)	
	R7	McGuirk, P. R., et al. "Synthesis and Structure-Activity Relationships of 7-Diazabicycloalkylquinolones, Including Danofloxacin, a New Quinolone Antibacterial Agent for Veterinary Medicine", J. Med. Chem. 35(4): 611-620 (February 1992)	
	R8	Slots, J., "Selection of Antimicrobial Agents in Periodontal Therapy", J. Periodont. Res., 37: 389-398 (2002)	

Examiner Signature	/Savitha Rao/	Date Considered	07/06/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.R./